

Saturday 19 June 2021

13:45–14:45 CET

Roche-sponsored virtual symposium

Adults with SMA: the beginning of a new chapter

Adults living with spinal muscular atrophy (SMA) have spent most of their lives without a disease-modifying therapy (DMT), depending on non-pharmacological approaches to manage their progressive disease. Now, in the DMT era, the management of adults with SMA is moving on to a new chapter—what does this look like?

Please join us for this virtual educational symposium where we will explore and discuss current approaches to the management of adults living with SMA and any remaining unmet needs, the urgency to treat this often-overlooked population, and their treatment goals and expectations for the future.

We look forward to welcoming you
to our virtual symposium!

Meet the faculty




Elena Mazzone
Catholic University,
Rome, Italy



Professor Maggie Walter
Ludwig Maximilian University,
Munich, Germany



Dr Giovanni Baranello
UCL Great Ormond Street Institute
of Child Health, London, UK



For more information about a Roche product or service, please scan the QR code with your mobile device, or visit <https://congressmi.roche.com/ean-2021.html>



This Roche-sponsored event is intended for healthcare professionals (HCPs) outside of the US. Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world. Risdiplam is approved by the European Medicines Agency for the treatment of 5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies, and is also approved by the US Food and Drug Administration for the treatment of SMA in adults and children 2 months of age and older. Prescribing information may vary depending on local approval in each country. This information is presented only for the purpose of providing a general overview of clinical trials and should not be construed as a recommendation for the use of any product for unapproved indications. Published by F. Hoffmann-La Roche Ltd, B4070, Switzerland. © 2021 All trademarks mentioned herein are protected by law. M-XX-00005202 | Date of preparation: May 2021